Certara Launches the SIVA Toolkit 2.0 to Improve Analysis of In Vitro Drug Development Data

PRINCETON, NJ - Apr 12, 2016 - Certara®, the global biosimulation technology-enabled drug development company, today launched the Simcyp In Vitro (Data) Analysis (SIVA) Toolkit 2.0 to assist drug development researchers with the analysis of complex in vitro studies. These studies are used to assess candidate drugs’ metabolism, transport and formulation properties.

“Global regulatory agencies are increasingly expecting sponsors to have a strong mechanistic understanding of drug metabolism, transport, and solubility/dissolution,” said Steve Toon, BPharm, PhD, President of Simcyp. “And the broader scientific community, including The International Transporter Consortium, which contains members of the U.S. Food and Drug Administration, are advocating the use of model-based approaches to maximize the value of data arising out of in vitro ADME studies. The SIVA Toolkit supports these types of data analyses which also in turn maximize the Simcyp® Population-based Simulator’s predictive capabilities.”

The most valuable biosimulation models have two things in common - they are built using the most appropriate and highest quality data. The SIVA Toolkit provides better, richer and more relevant data from in-vitro ADME experiments.

For example, permeability/transport assays measure how drugs move through the body, pass through cells, use transporters, get metabolized or a combination of all of them. While conventional in vitro analysis provides a single, global permeability value, the SIVA Toolkit generates parameters describing each of those physiological processes. SIVA’s approach ensures that researchers don’t lose any of that valuable information, which makes the resulting PBPK models more complete, powerful and relevant.

A standalone product, the SIVA Toolkit also allows researchers to optimize their in vitro ADME experiments, reducing the number of experiments and thus saving both time and money. It also gives sponsors more confidence to make important clinical trial decisions, such as determining whether they need to conduct certain studies.

It is a very user-friendly solution which features a predefined library of models for assessing drug metabolism, inhibition, transport and pharmaceutical formulation.

The SIVA Toolkit 2.0 now offers models for enzyme inhibition, allowing researchers to predict drug-drug interactions more accurately. It also includes Pharmaceutics-USP IV, Serial Dilution, Transfer and Two Phase Dissolution models.

Certara is also hosting a complimentary one-hour webinar entitled “SIVA Toolkit: Get the most from your in vitro data” on Thursday, April 14 at 11 a.m. EDT. To register for this event, please visit: http://bit.ly/1Xhfrjq.

About Certara
Certara is a global biosimulation and regulatory writing company, committed to optimizing drug development decisions. Its clients include hundreds of international biopharmaceutical companies, leading academic institutions, and key regulatory agencies. Certara’s solutions, which span drug discovery through patient care, increase the probability of regulatory and commercial success by using the most scientifically-advanced modeling and simulation technologies and regulatory strategies. For more information, visit www.certara.com.